EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis

Xiangjun Dai, Jun Yu, Li Niu, Xiao-Hua Chen

Frontiers in Medicine · 04.05.2026 · 13

DOI: 10.3389/fmed.2026.1807309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 04.05.2026. Verfasst von Xiangjun Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comprehensive Ophthalmology, Yiwu Aier Eye Hospital, Zhejiang, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Seasonal allergic conjunctivitis (SAC) is a common ocular allergic disease, predominantly affecting children and young adults, with no significant gender predominance.

Aim

This study aimed to retrospectively evaluate the clinical efficacy and safety of fluorometholone combined with azelastine eye drops versus azelastine monotherapy in patients with SAC.

Methods

This single-center retrospective study enrolled 180 SAC patients from January 2022 to June 2024. Patients were divided into a combination group (fluorometholone 0.1% QID + azelastine 0.05% BID, n = 90) and a monotherapy group (azelastine 0.05% BID, n = 90). Symptom and sign scores were assessed at baseline, weeks 1, 2, 4, and 2 months post-treatment. Efficacy, recurrence rate, and adverse events were compared.

Results

The combination group showed significantly greater reduction in symptom and sign scores from week 1 onward ( p < 0.01). At week 2, the total effective rate was 98.89% in the combination group versus 81.11% in the monotherapy group ( p < 0.05). The recurrence rate at 2 months post-treatment was significantly lower in the combination group (6.7% vs. 17.8%, χ 2 = 4.889, p = 0.027). Adverse events were mild and comparable between groups (5.6% vs. 4.4%, p = 0.697).

Conclusion

Fluorometholone combined with azelastine is more effective than azelastine monotherapy in treating SAC, providing faster symptom relief, higher efficacy, lower recurrence, and a comparable safety profile.

Schlagwörter

Stichwörter der Autor:innen

azelastinecombined therapyefficacyfluorometholoneretrospective analysissafetyseasonal allergic conjunctivitis

Autor:innen und Institutionen

  • Department of Comprehensive Ophthalmology, Yiwu Aier Eye Hospital, Zhejiang, China.
  • Department of Refractive Surgery, Yiwu Aier Eye Hospital, Zhejiang, China.

Zitieren

APA

Dai, X., Yu, J., Niu, L., & Chen, X. H. (2026). Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1807309

Vancouver

Dai X, Yu J, Niu L, Chen XH. Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1807309

BibTeX
@article{Dai2026,
  author = {Dai, Xiangjun and Yu, Jun and Niu, Li and Chen, Xiao-Hua},
  title = {Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1807309}
}
Kostenlos starten →